|
Apr 18
|
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
|
|
Apr 18
|
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
|
|
Apr 17
|
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
|
|
Apr 15
|
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
|
|
Apr 8
|
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
|
|
Apr 1
|
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 28
|
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
|
|
Mar 28
|
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
|
|
Mar 26
|
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
|
|
Mar 25
|
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
|
|
Mar 21
|
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
|
|
Mar 21
|
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders
|
|
Mar 18
|
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
|
|
Mar 12
|
NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
|
|
Mar 11
|
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
|
|
Mar 4
|
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
|
|
Mar 2
|
Positive Signs As Multiple Insiders Buy NRx Pharmaceuticals Stock
|
|
Mar 1
|
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share
|
|
Feb 27
|
/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./
|
|
Feb 26
|
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
|